Aarti Pharmalabs experienced a significant decline in Q4 profits by 31%, even with steady revenue figures. This dip resulted in a near 4% drop in the company's stock price at the beginning of trading on May 26, 2026.

Aarti Pharma's Q4 earnings showed a 21% decrease in EBITDA, dropping from ₹1.4B to ₹1.1B year-over-year. This decline also resulted in a narrowed margin of 19.4%, down from 25.4%.

Expert analysis suggests maintaining hold positions in Tata Power, NTPC, and Coal India, while considering buying HDFC Bank and Varun Beverages. Conversely, it's recommended to sell off shares of Indian Railway Finance Corp and Emmvee Photovoltaic Power due to technical and fundamental reasons.

Aarti Pharmalabs' latest Q4 report showcases an impressive portfolio of 220 products, 63 patents, and 7 USFDA-approved units. The company has made significant strides in the global Xanthine market, capturing a substantial 15-20% share. With a considerable R&D investment of INR 65 Crore and a team of 2,400 employees, Aarti Pharmalabs continues to innovate and grow.

Mirik Rajendra Gogri, a significant shareholder in Aarti Pharmalabs, has committed 3.08% of the company's shares to Bajaj Financial Securities and 360 One Distribution Services as collateral on March 25, 2026. This move could potentially impact the company's shareholding structure.